Bayes-Genis Antoni
Heart Institute, Hospital Universitari Germans Trias i Pujol Badalona, Spain.
Department of Medicine, Universitat Autònoma Barcelona Barcelona, Spain.
Eur Cardiol. 2022 Dec 20;17:e30. doi: 10.15420/ecr.2022.44. eCollection 2022 Feb.
It has been reported at the 2022 European Society of Cardiology Congress that the DELIVER trial has met its primary outcome - a relative reduction of 18% in a composite of worsening heart failure (HF) or cardiovascular death. These results, added to evidence from previously reported pivotal trials with sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with reduced and preserved heart failure (HF), provide compelling evidence of the benefit of SGLT2is across the HF spectrum, irrespective of ejection fraction. New diagnostic algorithms that are quick and easy to implement at the point of care are needed for quick diagnosis and implementation of these drugs. Ejection fraction may come later for proper phenotyping.
在2022年欧洲心脏病学会大会上报告称，DELIVER试验已达到其主要终点——心力衰竭（HF）恶化或心血管死亡复合终点相对降低18%。这些结果，再加上先前报道的钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）在射血分数降低和保留的心力衰竭（HF）患者中的关键试验证据，提供了令人信服的证据，证明SGLT2is在整个HF谱中均有益处，无论射血分数如何。需要快速且易于在护理点实施的新诊断算法，以便快速诊断并应用这些药物。射血分数可能稍后用于准确的表型分析。
